135 related articles for article (PubMed ID: 23348935)
1. Nuclear magnetic resonance imaging of tumour growth and neovasculature performance in vivo reveals Grb7 as a novel antiangiogenic target.
García-Palmero I; López-Larrubia P; Cerdán S; Villalobo A
NMR Biomed; 2013 Sep; 26(9):1059-69. PubMed ID: 23348935
[TBL] [Abstract][Full Text] [Related]
2. The adaptor Grb7 is a novel calmodulin-binding protein: functional implications of the interaction of calmodulin with Grb7.
Li H; Sánchez-Torres J; del Carpio AF; Nogales-González A; Molina-Ortiz P; Moreno MJ; Török K; Villalobo A
Oncogene; 2005 Jun; 24(26):4206-19. PubMed ID: 15806159
[TBL] [Abstract][Full Text] [Related]
3. Deletion of the calmodulin-binding domain of Grb7 impairs cell attachment to the extracellular matrix and migration.
García-Palmero I; Villalobo A
Biochem Biophys Res Commun; 2013 Jun; 436(2):271-7. PubMed ID: 23743201
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of growth factor receptor bound protein 7 suppresses angiogenesis by inhibiting the secretion of vascular endothelial growth factor A in ovarian cancer cells.
Xu Q; Liu Z; Zhu ZQ; Fan Y; Chen R; Xie XH; Cheng M
Bioengineered; 2021 Dec; 12(2):12179-12190. PubMed ID: 34783299
[TBL] [Abstract][Full Text] [Related]
5. Partners of wild type Grb7 and a mutant lacking its calmodulin-binding domain.
García-Palmero I; Shah N; Ali NA; Daly RJ; Wilce JA; Villalobo A
Arch Biochem Biophys; 2020 Jul; 687():108386. PubMed ID: 32360748
[TBL] [Abstract][Full Text] [Related]
6. Calmodulin regulates the translocation of Grb7 into the nucleus.
García-Palmero I; Villalobo A
FEBS Lett; 2012 May; 586(10):1533-9. PubMed ID: 22673522
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice.
Davidoff AM; Ng CY; Brown P; Leary MA; Spurbeck WW; Zhou J; Horwitz E; Vanin EF; Nienhuis AW
Clin Cancer Res; 2001 Sep; 7(9):2870-9. PubMed ID: 11555605
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
9. Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP.
Pratheeshkumar P; Kuttan G
Eur J Pharmacol; 2011 Apr; 656(1-3):10-8. PubMed ID: 21256125
[TBL] [Abstract][Full Text] [Related]
10. Role of growth factor receptor bound protein 7 in hepatocellular carcinoma.
Itoh S; Taketomi A; Tanaka S; Harimoto N; Yamashita Y; Aishima S; Maeda T; Shirabe K; Shimada M; Maehara Y
Mol Cancer Res; 2007 Jul; 5(7):667-73. PubMed ID: 17634422
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone in vascular pathology: neovascularization and expression of receptors is associated with cellular proliferation.
Lincoln DT; Singal PK; Al-Banaw A
Anticancer Res; 2007; 27(6B):4201-18. PubMed ID: 18225592
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect.
Szentirmai O; Baker CH; Lin N; Szucs S; Takahashi M; Kiryu S; Kung AL; Mulligan RC; Carter BS
Neurosurgery; 2006 Feb; 58(2):365-72; discussion 365-72. PubMed ID: 16462491
[TBL] [Abstract][Full Text] [Related]
14. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
15. Receptor-regulated dynamic interaction between endothelial nitric oxide synthase and calmodulin revealed by fluorescence resonance energy transfer in living cells.
Jobin CM; Chen H; Lin AJ; Yacono PW; Igarashi J; Michel T; Golan DE
Biochemistry; 2003 Oct; 42(40):11716-25. PubMed ID: 14529282
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast-enhanced and T2-weighted magnetic resonance imaging study of the correlation between tumour angiogenesis and growth kinetics.
Sathy BN; Chou YH; Li HJ; Chang C; Chow KP
Lab Anim; 2009 Jan; 43(1):53-9. PubMed ID: 19015174
[TBL] [Abstract][Full Text] [Related]
17. GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma.
Gotovac JR; Liu DS; Yates MJ; Milne JV; Macpherson AA; Simpson KJ; Eslick GD; Mitchell C; Duong CP; Phillips WA; Clemons NJ
J Pathol; 2020 Nov; 252(3):317-329. PubMed ID: 32737994
[TBL] [Abstract][Full Text] [Related]
18. Specific peptide ligand for Grb7 signal transduction protein and pancreatic cancer metastasis.
Tanaka S; Pero SC; Taguchi K; Shimada M; Mori M; Krag DN; Arii S
J Natl Cancer Inst; 2006 Apr; 98(7):491-8. PubMed ID: 16595785
[TBL] [Abstract][Full Text] [Related]
19. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
20. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice.
Abramovitch R; Dafni H; Smouha E; Benjamin LE; Neeman M
Cancer Res; 1999 Oct; 59(19):5012-6. PubMed ID: 10519416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
